Following this transaction Shai Gozani’s holding in the company was increased by 2.03% to a total of $312.4K. In addition to Shai Gozani, one other NURO executive reported Buy trades in the last month.
Based on Neurometrix’s latest earnings report from September 30, the company posted quarterly revenue of $3.39M and GAAP net loss of $3.91M. In comparison, last year the company earned revenue of $2.05M and had a GAAP net loss of $3.2M. The company has a one year high of $3.10 and a one year low of $1.26. Currently, Neurometrix has an average volume of 24.69K.
Starting in February 2012, NURO received 8 Buy ratings in a row.
The insider sentiment on Neurometrix has been positive according to 13 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
NeuroMetrix, Inc. is a health care company, which develops wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company markets the SENSUS Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. NeuroMetrix was founded by Shai N. Gozani in June 1996 and is headquartered in Waltham, MA.